Yes position
FDA approves Elevar Therapeutics' Rivoceranib + camrelizumab?
Ends Jul 23, 2026- Implied probability
- 41%
- Current value
- $8.2
- Potential payout
- $20
- Potential profit
- $11.8
- Multiplier
- 2.44x
- User PnL
- -$10
Polymarket Trader
0xc8262518e6f0dc3d451b39ff243920bbf6996c37
Current Predictions
Yes position
No position
Yes position
Yes position
Resolved Context
Yes position
No position
Trades
Latest visible trades for this Polymarket trader.